The present invention relates to a method for predicting the responsiveness ofcancer cells to FGFR inhibitors, which comprises the evaluation of the statusofFGFR1 gene and the status of MYC. A kit useful for carrying out the method isalsoprovided. In addition, a method of treating cancer such as lung cancer is alsoprovided which includes determining the status of FGFR1 gene and the status ofMYCgene, and administering to the cancer patient an FGFR inhibitor if the tumortissue orcells exhibit an increased expression or amplification of the FGFR1 gene, aswell asan increased expression or amplification of the MYC gene.
